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Background: Infringement by differentiated thyroid carcinoma on the brain is rare but, when suspected, the
patient deserves special attention. A patient with an enlarging metastasis of thyroid carcinoma to the skull
that was impinging on the brain illustrates diagnostic and therapeutic strategies applicable to the treatment of
metastatic carcinoma.
Methods: A case study was performed. Computed tomography (CT) and magnetic resonance imaging (MRI)
were done, serum thyroglobulin was measured, and tumor responses to thyroxine and 131I treatments were
monitored. Tumor dosimetry, enabled by scintigraphy with 131I employing single photon emission tomography
fused with CT (SPECT-CT), was performed.
Results: The metastasis was from a follicular variant of papillary thyroid carcinoma. During thyrotropin stim-
ulation the tumor enlarged. The tumor decreased in volume after each of two 131I therapies. Dosimetry indicated
delivery of 1970 and 2870 cGy to the tumor and 35 and 42 cGy to the brain, respectively, in the two treatments.
The patient has survived for more than 11 years since diagnosis.
Conclusions: A metastasis from a follicular variant of papillary carcinoma increased in volume during hypo-
thyroidism producing more infringement on the brain. Beyond the effects of thyroxine therapy, 131I treatments
induced recession of tumor volume. In patients with metastases that concentrate 131I, dosimetry with SPECT-CT
can predict absorbed doses of radiation to the tumor and to the adjacent organs and thus lay a basis for data-
based decisions on 131I therapies. Therapy may induce prolonged survival in patients with metastases infringing
on the brain.
Introduction
Bone is the only site of distant metastasis inabout 1.7% of patients with differentiated thyroid car-
cinoma (1), and the 5-year cause-specific survival for those
with papillary carcinoma is about 10% (2). Skeletal de-
posits of neoplasm pose special hazards of fracture and,
when adjacent to the central nervous system, neurologic
impairment. In addition, stimulation by thyrotropin (TSH)
may produce swelling of metastases and abrupt clinical
deterioration. Radiation therapy, including that from radio-
iodine, adds danger of injury to the adjacent neural struc-
tures.
A case report exemplifies the concerns in treating a patient
with a large papillary thyroid carcinoma that was impinging
on the brain. Responses to 131I treatments were monitored,
and dosimetries of 131I in the tumor and the adjacent brain tis-
sue were assessed.
Case Report
In 1997, at age 65 years, the patient developed a posterior
head swelling. In another hospital, computed tomography
(CT) and magnetic resonance imaging (MRI) images dem-
onstrated a tumor, 84.8 cm, traversing the skull and in-
truding upon his brain, but he had no neurological symptoms.
Biopsied tissue revealed what was ultimately defined as the
follicular variant of papillary carcinoma (Fig. 1). Attempts at
resection were foiled by copious bleeding. Embolization of
tumor vessels failed to reduce the carcinoma. After a total
thyroidectomy, scintigraphy during hypothyroidism por-
trayed 131I concentration in the tumor but no other metastasis.
The patient received 5.8 GBq (156 mCi) of 131I as treatment; no
symptoms ensued. The swelling subsided. A 131I image in
2003 showed faint radioactivity in his posterior skull.
In November 2006, progressive head swelling reappeared.
In January 2007, MRI depicted a tumor of substantial size
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extending across the posterior midline and infringing
on the brain (Table 1, Fig. 2A). In March 2007, at the University
of Michigan Health System, the patient appeared well except
for the tumor. Neurologic examination detected only a slight
left facial synkinesis. Medications were quinapril for hyper-
tension, calcium supplement, and levo-thyroxine (Synthroid,
Abbott Laboratories North Chicago, IL). Another attempt at
surgical reduction provoked much bleeding. A biopsy was
obtained, and the operation was then abandoned.
In July 2007, his thyroxine (0.2 mg=d) was withdrawn for 4–
5 weeks. During this interval, his head swelling noticeably
increased; his only other symptom was fatigue. At that time,
CT demonstrated that the tumor had tripled its volume since
January (Table 1, Fig. 3A). The images and dosimetric mea-
surements were made after he ingested 131I, 37 MBq (1 mCi);
these studies included single photon emission tomography
fused with CT (SPECT-CT); the only abnormal focus of ra-
dioactivity was in the tumor (Table 1, Fig. 3B). SPECT-CT of
his neck and thorax and whole body planar images disclosed
no other tumor. He then received 7.4 GBq (200 mCi) of 131I;
4 days later, images portrayed no additional focus of radio-
activity within the patient. One day after treatment he resumed
thyroxine therapy. Dexamethasone (5 mgfour timesaday)was
initiated at the time of 131I treatment; the dose was tapered
after 1 week. Other than anxiety from dexamethasone, no un-
toward symptoms developed.
By November, it was apparent to the patient and his phy-
sicians that the swelling was much reduced; the diminution of
tumor size was documented on MRI images (Table 1, Fig. 2B).
Thyroxine was again discontinued for 4–5 weeks, and no-
ticeable swelling gradually recurred, but again the only other
clinical change was fatigue. The investigations were repeated
in December: on SPECT-CT the tumor was larger than in
November, but smaller than in July; and serum thyroglobulin
(Tg) concentrations (with absent Tg antibodies) followed a
similar pattern (Table 1). A third therapy with 131I, 7.5 GBq
(203 mCi) was administered along with dexamethasone at a
lower dose than that following his treatment in July. Thyroxine
FIG. 1. Photomicrograph of tumor biopsy; original mag-
nification,200. Well-differentiated papillary carcinoma,
follicular variant. The tumor has a pure follicular architecture
while the tumor cells display the characteristic features of
papillary carcinoma: nuclear enlargement and elongation
and prominent nuclear grooves (6). Color image available
online at www.liebertonline.com=thy.
Table 1. Thyroid Metastasis
Jul 07 Dec 07




8 days Nov 07 pre Rx Rx Jun 08 Nov 08
TSH (mU=L) 0.4 75 0.4 84 0.1 2.1
Tg (ng=mL) 6145 29124 3321 9140 530 1607
Treatments
thyroxine (mg=d) 0.2 0 0.2 0.2 0.2 0 0.228 0.228
131-I (GBq) 7.4 7.5
Tumor Measurements
volume methoda MRI CT CT MRI MRI CT MRI MRI




effective half life (d)
from fractional uptakesb 1.7 1.7
assumedc 3 3
residence time (h)
from fractional uptakesb 5.3 5.3
assumedc 9.4 9.4
absorbed dose (cGy)
from fractional uptakesb 1970 2870
assumedc 3470 5055
afor details of method see text.
bcalculated from uptake at day 1 of 6% (Dec 07) and at day 2 of 4% ( Jul 07).
cassumed effective half life of 3 days.
TSH, thyrotropin; Tg, thyroglobulin; MRI, magnetic resonance imaging; CT, computed tomography; Rx, treatment.
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was resumed, and because his cardiovascular status appeared
stable, the prescription was increased to 0.225 mg=d. In June
2008, he was feeling quite well. Tumor volume and Tg level
were each reduced below the values obtained in November
2007 (Table 1).
In November 2008, the tumor size was again smaller (Fig.
2C). He continued to feel well, and clinical evaluation in-
cluding neurologic examination was unchanged. The level of
Tg was higher than that in June 2008, but his TSH (2.1 mU=L)
was no longer suppressed (Table 1). Thyroxine dose was fur-
ther increased to 0.257 mg=d.
Additional 131I treatment is possible and will depend upon
the patient’s clinical course.
Methods
Before each of two therapies, diagnostic studies followed
ingestion of 37 MBq (1 mCi) of 131I.
Body dosimetry
Whole body retention of 131I after 2 days was determined
by scintigraphic probe aimed at the patient’s body, 2.5 m
distant, and related to the administered activity (3).
MRI and SPECT-CT
MRI images were obtained on a Phillips 3.0 Tesla magnet
(Siemens Medical Solutions, Malvern, PA) utilizing intrave-
nous gadolinium (Magnevist) contrast medium Siemens
Medical Solutions Malvern, PA. Two days after ingestion of
diagnostic 131I, co-registered SPECT-CT images were ac-
quired on a Siemens Symbia T6 SPECT=CT dual-head gamma
camera (Siemens Medical Solutions, Malvern, PA). No con-
trast medium was employed for the CT. Scintigraphic data
were obtained using 64 steps (20 seconds=stop) in a noncir-
cular orbit over 3608. Tomographic images were in a 128
128 matrix using 3-dimensional ordered-subset expectation
maximization iterative reconstruction technique (eight itera-
tions, four subsets), and a CT-based correction algorithm for
attenuation was applied. CT images were made with param-
eters of 130 kV and 100 mAS; reconstruction was from 5 mm
slices in a 512512 matrix.
Tumor volume
In MRI and CT images, tumor volumetric measure-
ments were obtained with Vitrea 2 software, version 4.1.1.0
(Vital Images, Inc., Minnetonka, MN). Free-hand sculpting
FIG. 2. MRI transaxial images of the patient’s head at the same anatomic level over time during thyroxine therapy. Tumor
was electronically isolated. (A) January 2007; TSH (in May) 0.4 mU=L; 2A-1 MRI and 2A-2 tumor with volume of 74 mL; (B)
November 2007 (following 131I treatment in July); TSH 0.4 mU=L; 2B-1 MRI and 2B-2 tumor with volume of 121 mL. (C)
November 2008 (following 131I treatments in July and December 2007); TSH 2.1 mU=L; 2C-1 MRI and 2C-2 tumor with
volume of 72 mL. Color image available online at www.liebertonline.com=thy.
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of the tumor boundaries excluded tumor from surrounding
structures and the volume of the tumor was then generated
for each time of imaging.
Tumor dosimetry
Radioactivity in the tumor was also determined by scinti-
graphic probe at 2.5 m and related to the administered activity
of 131I, but acquisitions were not systematically planned. Be-
fore the first treatment, tumor activity was 4% at 2 days; and
before the second treatment tumor activity was 6% at 1 day.
The effective half life of 131I in the tumor was estimated from
these two values.
Tumor time-activity measurements from the scintigraphic
probe data (above) were combined with the 3D dose-rate
distribution from a Monte Carlo based calculation to obtain
the average absorbed dose to the tumor and brain. The Dose
Planning Method (DPM), a Monte Carlo electron and photon
transport program (4), was designed for radiation absorbed-
dose computations in external beam radiotherapy; it was
adapted and validated for applications in internal emitter
therapy (5). In the present study, the inputs to DPM were the
co-registered SPECT images, CT-derived density map, and
the CT-defined masks for tumor and brain regions. The SPECT
and CT matrix size was 512512115 with a voxel size of
0.98 mm0. 98 mm2 mm. The field-of-view covered the brain
and neck regions. The tumor and brain were outlined ac-
cording to the contour seen on CT and independent of SPECT
images. The output from DPM was the 3D absorbed dose-rate
distribution, the absorbed dose-rate averaged over the tumor,
and the absorbed dose-rate averaged over the brain.
For this case report, the University of Michigan Internal
Review Board waived any requirement for consent.
Results
Histopathology
The thyroid metastasis biopsy in March 2007 exhibited a
follicular-patterned neoplasm with many colloid-filled folli-
cles. At higher magnification, the characteristic nuclear fea-
tures of papillary carcinoma were fully developed, including
nuclear enlargement and elongation and numerous nuclear
grooves. Thus, the diagnosis of well-differentiated papillary
carcinoma, follicular variant was rendered (6).
Body dosimetry
At 2 days, levels of body retention of the diagnostic 131I
were 20% and 23% before the treatments with 131I in July and
December 2007, respectively. Each was in a range wherein
high activities of 131I were unlikely to induce body and bone
marrow toxicity (4). Complete blood counts were normal in
July and December 2007.
Tumor images, volumes, and serum Tg
According to the patient, the tumor was enlarging over the
months since late 2006. Between January and July 2007, the
expansion was from 74 to 219 mL, and there was more in-
fringement of brain (Table 1; Figs. 2A and 3A). However, it is
not clear how much of the amplification took place during the
4–5 weeks of thyroxine deprivation and consequential rise in
serum TSH level in preparation for 131I treatment in July.
FIG. 3. Images in July 2007 1 day before 131I treatment. TSH 75 mU=L. CT transaxial images of the head were obtained at a
different inclination from the MRI images in Fig. 2, but both CT and MRI portray tumor at maximum dimensions. (A1) 1, CT
image and (A2) tumor with volume of 219 mL. (B) Single photon emission tomography fused with CT (SPECT-CT) dem-
onstrating radioactivity concentration in tumor. (C) CT with superimposed iso-dose levels of cGy in the tumor (shaded) and
brain. The absorbed dose to the brain is from gamma (photon radiation) emanating from the tumor. Mean radiation dose to
the tumor was 1970 cGy. Color image available online at www.liebertonline.com=thy.
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Concentration of Tg rose from a May 2007 baseline of 6145 to
29,124 ng=mL in July (Table 1).
Thyroxine therapy was instituted the day after the July
2007 131I treatment. Four days post-treatment, SPECT-CT
evaluation of the distribution of 131I, and CT showed the
tumor volume unchanged. But 8 days after treatment, MRI
disclosed a decrease in tumor volume to 169 mL (Table 1).
With continued thyroxine therapy and diminution of TSH, the
tumor declined to 121 mL in November 2007.
After thyroxine was discontinued for 4–5 weeks in De-
cember 2007, the carcinoma again enlarged, but only to 155 mL
(128%), and, under the same level and duration of TSH stim-
ulation, the tumor volume was 71% of that before the 131I
treatment in July (Table 1). Compared to the baseline in May
2007, Tg decreased in November 2007 to 3321 ng=mL, but
again rose to 9140 ng=mL (275%) in December 2007. Still, the
Tg in December was less (31%) than in July (Table 1). These
changes from July were attributed to the 131I radiation.
Subsequent to the 131I treatment in December 2007 and
with resumption of thyroxine therapy, the tumor abated from
121 mL in November 2007 to 110 mL (91%) in June and to
72 mL (60%) in November 2008, respectively (Table 1, Fig.
2C). From November 2007, Tg declined from 3321 to 530 ng=
mL (16%) in June, but it increased to 1607 ng=mL in Novem-
ber 2008; the latter Tg value was associated with a slight rise in
TSH (Table 1). These decrements in tumor volume and Tg
level were attributed to the 131I treatment in December.
It was clear that, on each occasion, cessation of thyroxine
therapy was followed by enlargement of the tumor and in-
fringement of the brain concomitant with the rise in serum
TSH. However, an inherent growth of tumor between January
2007 and before the hypothyroidism in July 2007, may have
accounted for a substantial component in the volume before
the 131I treatment in July. Thus, despite evidence for 131I
treatment effects (see above), no difference in tumor size was
found between January 2007 and November 2008 (Table 1).
Comparing the baseline Tg concentration in May 2007
(6145 ng=mL) with the Tg concentration in November 2008
(1607 ng=mL) gives evidence of 131I reductive effects and
supports this explanation for the discrepancy between the
observed tumor diminution after each 131I therapy but an
absence of overall tumor change from January 2007 to No-
vember 2008. It is not clear whether the change in volume 8
days after 131I treatment and resumption of thyroxine therapy
(Table 1) was a consequence of radiation-induced tumor dis-
solution, TSH decline, or both.
Tumor dosimetry
Dosimetry was carried out retrospectively; some mea-
surements, particularly tumor uptakes of 131I, had not been
made systematically. Yet, with certain assumptions, predic-
tions of absorbed doses of radiation can be reasonably esti-
mated. Assuming that tumor uptake of the administered 131I
activity of 6% of the administered activity on day 1 (as mea-
sured in December 2007) and of 4% on day 2 (as measured on
July 2007) were representative of the values before each
treatment, then an effective half life of 131I can be assumed,
from a mono-exponential fit, to be 1.7 days (Table 1). When
this estimate is applied to the 131I treatment in July 2007, a
residence time was calculated, and with the tumor volume
and treatment activity the tumor absorbed dose was estimated
to be 1970 cGy (rad). The cGy seemed low for the amount of
tumor diminution so an additional effective half life was as-
sumed to be 3 days (Table 1). From this assumption, the ab-
sorbed dose was proportionally increased to 3470 cGy. The
radioactivity concentrations in the tumor in July are portrayed
in Fig. 3B,C.
Similar calculations and assumptions were made for the
131I treatment in December 2007. The absorbed doses of ra-
diation for the effective half lives of 1.7 and 3 days were, re-
spectively, 2870 and 5055 cGy (Table 1). The absorbed doses
were higher in December because the tumor volume was
smaller, the concentration of 131I was then proportionally
larger, and the estimated=assumed effective half lives were
unchanged.
Brain dosimetry
CT images indicated that the tumor was separated from the
brain by meninges. Thus, very little of beta electron energies,
which are deposited largely within 2 mm of disintegrations,
would reach the brain. Radiation to the brain was assumed to
be from the gamma photons of 131I emanating from the tumor,
and estimations were then made of the absorbed doses. During
the July 131I treatment, the overall brain received a mean of
35 cGy; at 1–2 cm distance from the tumor, 100 cGy was im-
parted (Fig. 3C). From the December treatment, a mean of
42 cGy was delivered to the brain.
Discussion
Distant metastases are rare from the follicular variant of
papillary carcinoma; in 37 patients none exhibited distant
metastases (7). Care must be taken to distinguish this variant
from follicular carcinoma; the diagnosis in our patient is es-
tablished by the presence of the nuclear changes characteristic
of the variant (6). The large follicles filled with colloid may
predispose to 131I concentration and retention. Our patient’s
clinical course was unusual for papillary carcinomas because
he developed a single metastasis.
From the outset, swelling from a skull metastasis was ap-
parent to the patient and readily appreciated on clinical
examination as well as on MRI and CT images. Our obser-
vations confirm that, consequential to TSH stimulation, well-
differentiated thyroid carcinomas can expand within a few
weeks. Because the patient’s skull was not intact, there was
ample room for decompression during hypothyroidism. With
resumption of thyroxine therapy, both tumor volume and Tg
concentration receded. The risks of thyroxine in superphy-
siologic doses (e.g., atrial fibrillation) must be weighed against
the obvious benefits on tumor suppression; possibly TSH
levels of 0.2–0.4 mU=L will be optimal. In our patient,
there appeared to be no immediate tumor expansion follow-
ing 131I therapy. Whether the steroid therapy suppressed tu-
mor swelling in response to the radiation was impossible to
assess.
If one concludes that the carcinoma in our patient grew
between the MRI assessment in January 2007 and before
thyroxine cessation in July 2007, then there is reasonable ev-
idence that each of the two 131I treatments diminished tumor
volume. At each time point the percentage change in Tg ex-
ceeded that of tumor volume, making Tg a more sensitive
index of tumor modulation. Since tumor volume contracted
between June and November 2008, while the Tg level rose, the
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Tg reflected a recent alteration, one related to the slight rise in
TSH or to tumor resurgence.
Quantifying absorbed radiation in the tumors has generally
eluded therapists in the past, but with the development of
scintigraphic images fused with CT, dosimetry of 131I in me-
tastases and their environs is now possible (4). The radiation
imparted to the tumor of our patient was calculated to
be 1970 cGy in the July treatment and 2870 cGy in December.
These estimates were less, but possibly more accurate, than
the absorbed doses (measured by two-dimensional planar
scintigaphy) that were deemed effective in eliminating thyroid
metastases; i.e.,>8000 cGy (8) and>2900 cGy (9). In addition,
7700–14,000 cGy have reduced goiter volumes (10).
Radiation from 131I imparted to the brain was from the
gamma photons and relatively weak (100 cGy). Patients
have tolerated external beam radiation to brain metastases
from breast carcinoma when 2000 cGy were delivered in
two treatments over a week (11). Unless tumor and neuronal
cells are in intimate contact, 131I radiation to the brain from
treatment of thyroid metastases is likely to be inconsequential
even when higher absorbed doses are delivered to the thyroid
carcinomas.
In an evaluation of 988 patients with differentiated thyroid
carcinoma, 20% of the 85 with distant metastases exhibited
these only in bone (1.7% of all patients) (1). In the same
category, those with papillary carcinoma had a 5-year cause-
specific survival of 10% (2). Similar findings have subse-
quently appeared in two publications on patients with distant
metastases from differentiated thyroid carcinoma. Only bone
metastases were found in 25% of 444 patients (12) and in
24% of 111 patients (13). Of those with only bone metastases,
72% manifested 131I-concentrating tumors (12) and the 10-year
cause-specific survival was 25% (13). Bone metastases that re-
sult in fracture undoubtedly contributed to the mortality. Tu-
mors infringing on brain are rare but may be more hazardous.
Our patient exemplifies the potential for differentiated
thyroid carcinomas to expand during TSH stimulation. As a
warning, in seven patients who had intracerebral metastases,
marked neurological symptoms developed during hypothy-
roidism (14–18). It is not known if the gradual changes during
hypothyroidism could be more easily managed than the
abrupt swelling of metastases that will follow recombinant
human TSH (rhTSH) injections. If rhTSH is employed, the
patient should be placed under continuous observation since
within hours after single injections of rhTSH, thyroid gland
enlargements were observed: 24% in goitrous tissues follow-
ing 0.3 mg (19) and 36% in normal tissues after 0.9 mg (20).
Also, goiter volumes have increased following 131I radiation
(21), and in the same circumstances tumor enlargement could
also occur. Because devastating tumor volume increments may
follow TSH stimulation (14,16), surgical decompression of me-
tastases near or in the brain should be considered before diag-
nostic investigations and therapy with 131I are undertaken.
If one assumes that a functioning metastasis of well-
differentiated thyroid carcinoma is treatable by 131I, then
dosimetry of normal tissues will likely provide the upper limit
of prescribed activity (3,22). With SPECT-CT, accurate do-
simetry of tumor and surrounding organs is now feasible, and
results from these measurements may determine the amount
of radioactivity necessary for beneficial effect. If the absorbed
dose of radiation from 131I is found to be inadequate to the
task, consideration can be given to external beam radiation.
As in our patient, steroid therapy has been administered with
the hope of reducing tumor swelling (14,16), but the efficacy
of this measure in reducing TSH-stimulated tumor swelling is
unknown.
In summary, we present a patient who is unusual in many
respects. A large solitary metastasis from follicular variant of
papillary thyroid carcinoma infringed on his brain. The tumor
enlarged during hypothyroidism but produced no symptoms
probably because a skull defect allowed decompression; great
care must be taken to avoid the devastating consequences of
tumor swelling from TSH stimulation in patients with brain
metastases. The tumor decreased in volume and in release of
Tg after two treatments with 131I; thyroxine therapy produced
added benefit. Dosimetry, enabled by SPECT-CT, determined
that with each 131I treatment>1900 cGy of absorbed radiation
was imparted to the tumor and 42 cGy to the brain. How-
ever, patients suspected of metastases adjacent to or involving
neural tissues must be evaluated with cognizance of the pit-
falls from TSH stimulation. Since the tumor was diminished
by 131I treatments and by thyroxine therapy, it is probable that
each modality played a role in the patient’s survival of more
than 11 years. In the future, tumor dosimetry may determine
how much 131I is required to reduce and eliminate thyroid
carcinoma.
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